Q-omics provides the consensus-scored RAB19 profile across patient tissues and cancer cell-line models. RAB19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB19 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, RAB19 RNA expression shows 18,339 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where RAB19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB19 survival associations across molecular data types. RAB19 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB19 RNA expression–survival associations across cancer types. High RAB19 expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRC, KIRP, BLCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB19 RNA expression.
This table summarizes RAB19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB19 shows lower tumor expression in KIRC and higher tumor expression in LUAD, BLCA, STAD, BRCA and UCEC. The LUAD box plot shows higher RAB19 RNA expression in tumor versus normal tissue (log2 FC = +1.471, t-test p < 0.001).
This table shows molecular features associated with RAB19 in patient tissues and cancer cell lines. In patient samples, RAB19 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
